Biotech CEOs: Can Scientist-Founders Remain In Charge?

A New Breed Of Scientist-Founder: PhD-Carrying Entrepreneurs Who Want To Translate Their Ideas Into Companies

Founder-CEOs do not typically remain at the helm as biotechs mature. Exceptions to that rule are multiplying, though, especially in Europe as companies aim directly for Nasdaq.

Captain
When do scientific founders stay at the helm of their biotech businesses? • Source: Shutterstock

There are several high-profile examples of biotech leaders who have seeded, nurtured and grown their companies into profitable, sustainable organisations. Josh Boger founded Vertex Pharmaceuticals Inc. in 1989 and was CEO for twenty years, building a $43bn behemoth. Jean-Paul Clozel, with wife Martine and two co-founders, built Actelion Pharmaceuticals Ltd. into Europe’s largest, most successful biotech, finally succumbing to a $30bn offer from Johnson & Johnson in 2017. Art Levinson – not a founder, but a very early employee at Genentech Inc. – was promoted from R&D chief to CEO in 1995, defying skeptics to build the industry leader. The message from these success stories: science rules, not just at the start, but all the way.

These individuals are exceptional, however. Few combine the broad skill set (and dogged perseverance) required to discover and fund a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from C-Suite Speaks

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success. 

How Vir Bio CEO Marianne De Backer Is Rebuilding Commercial Momentum

 
• By 

From billion-dollar COVID antibody to a strategic reset, Marianne De Backer is navigating Vir's comeback through pipeline focus and disciplined leadership.

More from Leadership

The Goldilocks Isotope: Perspective Therapeutics’ ‘Just Right’ Alpha Radiotherapeutic

 
• By 

Thijs Spoor's bet on lead-212 is paying off as Perspective Therapeutics advances three clinical programs with promising early efficacy signals and a comprehensive manufacturing strategy.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.

Rising Leaders 2025: Emma Hodcroft On Taking Initiative When “Plan A” Falls Short

 

Emma Hodcroft, co-founder of Pathoplexus and a key Nextstrain contributor, stresses the importance of career flexibility for young scientists. She urges early-stage researchers to embrace curiosity, using her unconventional path as an example of how curiosity can lead to impactful success.